Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 3,166,818 shares, an increase of 20.5% from the December 15th total of 2,628,101 shares. Currently, 17.1% of the company’s shares are sold short. Based on an average trading volume of 2,555,483 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 2,555,483 shares, the days-to-cover ratio is currently 1.2 days. Currently, 17.1% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of brokerages recently commented on CTXR. D. Boral Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Citius Pharmaceuticals in a research report on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, December 27th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Arkadios Wealth Advisors raised its position in Citius Pharmaceuticals by 100.0% during the 2nd quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after purchasing an additional 10,000 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals during the second quarter valued at approximately $32,000. Finally, NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals during the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Stock Down 5.5%

Shares of Citius Pharmaceuticals stock opened at $0.81 on Wednesday. The firm has a market cap of $16.83 million, a PE ratio of -0.24 and a beta of 1.56. Citius Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.40. The company’s fifty day simple moving average is $1.02 and its two-hundred day simple moving average is $1.26.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.